Partial agonist-like profile of the cannabinoid receptor antagonist SR141716a in a food-reinforced operant paradigm

Behavioural Pharmacology

Volumn 15, Issue 1, 2004, Pages 13-20

  De Vry, J ^a,b   Jentzsch, K R ^a  

^a CNS Research   (Germany)

^b GRÜNENTHAL GMBH   (Germany)

Author keywords

9 tetrahydrocannabinol; CP 55,940; Rat; SR141716A; WIN 55, 212 2

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; CANNABINOID RECEPTOR; DRONABINOL; RIMONABANT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG ANTAGONISM; INSTRUMENTAL CONDITIONING; MALE; NONHUMAN; RAT; RECEPTOR BINDING; REINFORCEMENT;

ANIMALS; APPETITIVE BEHAVIOR; CANNABINOIDS; CONDITIONING, OPERANT; CYCLOHEXANOLS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; EXCITATORY AMINO ACID ANTAGONISTS; MALE; MORPHOLINES; MOTIVATION; NAPHTHALENES; PIPERIDINES; PREMEDICATION; PYRAZOLES; RATS; RATS, WISTAR; RECEPTOR, CANNABINOID, CB1; REINFORCEMENT SCHEDULE; TETRAHYDROCANNABINOL;

EID: 1242294553     PISSN: 09558810     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008877-200402000-00002     Document Type: Article

References (26)

1. Breivogel CS, Childers SR (2000). Cannabinoid agonist signal transduction in rat brain: comparison of cannabinoid agonists in receptor binding, G-protein activation, and adenylyl cyclase inhibition. J Pharmacol Exp Ther 295:328-336.
2. Carriero D, Aberman J, Lin SY, Hill A, Makriyannis A, Salamone JD (1998). A detailed characterization of the effects of four cannabinoid agonists on operant lever pressing. Psychopharmacology (Berl) 137:147-156.
3. 9-tetrahydrocannabinol. J Pharmacol Exp Ther 263:1118-1126.
4. De Vry J, Jentzsch KR (2002). Discriminative stimulus effects of BAY 38-7271, a novel cannabinoid receptor agonist. Eur J Pharmacol 457:147-152.
5. De Vry J, Jentzsch KR (2003). Intrinsic activity estimation of cannabinoid CB, receptor ligands in a drug discrimination paradigm. Behav Pharmacol 14:471-476.
6. 1/2 receptor agonists in a limited-access operant food intake paradigm in the rat. Eur Neuropsychopharmacol 13:337-345.
7. De Vry J, Jentzsch KR, Kuhl E, Eckel G (2004a). Behavioral effects of cannabinoids show differential sensitivity to cannabinoid receptor blockade and tolerance development. Behav Pharmacol 15:1-12.
8. De Vry J, Schreiber R, Eckel G, Jentzsch KR (2004b). Behavioral mechanisms underlying inhibition of food-maintained responding by the cannabinoid receptor antagonist/inverse agonist SR141716A. Eur J Pharmacol 483:55-63.
9. Freedland CS, Poston JS, Porrino LJ (2000). Effects of SR141716A, a central cannabinoid receptor antagonist, on food-maintainad responding. Pharmacol Biochem Behav 67:265-270.
10. Gaoni Y, Mechoulam R (1964). Isolation, structure and partial synthesis of an active constituent of hashish. J Am Chem Soc 83:1646-1647.
11. Gifford AN, Bruneus M, Gatley SJ, Lan R, Makriyannis A, Volkow ND (1999). Large receptor reserve for cannabinoid actions in the central nervous system. J Pharmacol Exp Ther 288:478-483.
12. 8-tetrahydro-cannabinol in rats and pigeons. J Pharmacol Exp Ther 250:1000-1005.
13. 9-THC as discriminative stimuli in rats: tests with the cannabinoid antagonist SR-141716 and the endogenous ligand anandamide. Psychopharmacology 156:369-380.
14. 9-THC and the CB1 receptor antagonist SR-141716 in rats: open-field revisited. Pharmacol Biochem Behav 73:911-919.
15. 9-tetrahydrocannabinol-induced operant rate decreases in rats are not readily antagonized by SR-141716A. Eur J Pharmacol 466:121-127.
16. Johnson MR, Melvin LS (1986). The discovery of nonclassical cannabinoid analgesics. In: Mechoulam R (editor): Cannabinoids as Therapeutic Agents. Boca Raton: CRC Press; pp. 121-145.
17. Kirkham TC, Williams CM (2001). Endogenous cannabinoids and appetite. Nutr Res Rev 14:65-86.
18. Mansbach RS, Rovetti CC, Winston EN, Lowe JA III (1996). Effects of the cannabinoid CB1 receptor antagonist SR141716A on the behavior of pigeons and rats. Psychopharmacology (Berl) 124:315-322.
19. Mauler F, Mittendorf J, Horváth E, De Vry J (2002). Characterization of the diarylether sulfonylester (-)-(R)-3-(2- hydroxymethylindanyl-4-oxy)phenyl-4,4,4-trifluoro-1-sulfonate (BAY 38-7271) as a potent cannabinoid receptor agonist with neuroprotective properties. J Pharmacol Exp Ther 302:1-10.
20. Pério A, Barnouin M-C, Poncelet M, Soubrié P (2001). Activity of SR141716 on post-reinforcement pauses in operant responding for sucrose reward in rats. Behav Pharmacol 12:641-645.
21. 9-tetrahydrocannabinol and antagonist activity of cannabidiol on rat brain cannabinoid receptors. Life Sci 63:1-6.
22. Rinaldi-Carmona M, Barth F, Héaulme M, Shire D, Calandra B, Congy C, et al. (1994). SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett 350:240-244.
23. Sim-Selley LJ, Brunk LK, Selley DE (2001). Inhibitory effects of SR141716A on G-protein activation in rat brain. Eur J Pharmacol 414:135-143.
24. Solinas M, Panlilio LV, Antoniou K, Goldberg SR (2003). The cannabinoid CB1 antagonist N-piperidinyl-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl- pyrazole-3-carboxamide (SR-141716A) differentially alters the reinforcing effects of heroin under continuous reinforcement, fixed ratio, and progressive ratio schedules of drug self-administration in rats. J Pharmacol Exp Ther 306:93-102.
25. 9-tetrahydrocannabinol in rats and rhesus monkeys. J Pharmacol Exp Ther 275:1-6.
26. Wiley JL, Barrett RL, Lowe J, Balster RL, Martin BR (1995b). Discriminative stimulus effects of CP 55,940 and structurally dissimilar cannabinoids in rats. Neuropharmacology 34:669-676.